Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA
Loading...
Identifiers
Publication date
Authors
Rubín de Célix, Cristina
Ricart, Elena
Martín Arranz, María Dolores
Francisco, Ruth de
García Alonso, Francisco Javier
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
Real-world data on dose escalation/de-escalation in inflammatory bowel disease (IBD) are scarce.
In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De-escalation is feasible in some patients. Re-escalation is generally effective after relapse.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Rubín De Célix, C., Ricart, E., Martín‐Arranz, M. D., De Francisco, R., García‐Alonso, F. J., Mesonero, F., Gomollón, F., De Castro, L., Ramos, L., García‐López, S., Arias, L., Mañosa, M., Iglesias, E., Calvet, X., Suria Bolufer, C., Casanova, M. J., Pérez‐Calle, J. L., Giordano, A., Sierra‐Ausín, M., … Gisbert, J. P. (2026). Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics, 63(1), 93-108. https://doi.org/10.1111/apt.70312